Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer

Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). The present study investigated combinations of gemcitabine with antiangiogenic agents of various mechanisms for PDAC, including bevacizumab (Bev), sunitinib (Su) and EMAP II. Cell proliferation and protein ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Zhang, Changhua, Ruan, Winston, Schwarz, Margaret A., Schwarz, Roderich E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377661/
https://www.ncbi.nlm.nih.gov/pubmed/22723862
http://dx.doi.org/10.1371/journal.pone.0038477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377661/
https://www.ncbi.nlm.nih.gov/pubmed/22723862
http://dx.doi.org/10.1371/journal.pone.0038477

Ejemplares similares